FDA Oncology Announcements

VEGFR inhibitor × Endocrine × Clear all

5 Announcements

FDA approves cabozantinib for adults and pediatric patients 12 years of age and older with pNET and epNET

Drug: Cabometyx (cabozantinib) · VEGFR inhibitor
Conditions: EndocrineGastrointestinal

FDA approves cabozantinib for differentiated thyroid cancer

Drug: Cabometyx (cabozantinib) · VEGFR inhibitor
Condition: Endocrine

Sorafenib (NEXAVAR)

Drug: NEXAVAR tablets (sorafenib) · VEGFR inhibitor
Conditions: EndocrineGastrointestinalGenitourinary

Cabozantinib

Drug: COMETRIQ capsules (cabozantinib) · VEGFR inhibitor
Condition: Endocrine

Sunitinib

Drug: Sutent Capsules (sunitinib) · VEGFR inhibitor
Conditions: EndocrineGastrointestinalNET